Pharming Group NV
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Orphan and Rare Disease
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases.
Company HQ City:
Leiden
Company HQ State:
South Holland
Company HQ Country:
Netherlands
Year Founded:
1988
Lead Product in Development:
RUCONEST - treatment of acute hereditary angioedema (HAE) attacks
Joenja (leniolisib) - treatment of Activated Phosphoinositide 3-kinase Delta (PI3Kδ) Syndrome (APDS)
Napazimone - mDNA primary mitochondrial disease
CEO
Fabrice Chouraqui, MBA,PharmD
Development Phase of Lead Product
Multiple Products in Market
Exchange
Nasdaq
Ticker
PHAR
When you expect your next catalyst update?
H2 '26
What is your next catalyst (value inflection) update?
Leniolisib Ph 2 clinical trials in PIDs with immune dysregulation topline data
Napazimone pivotal FALCON clinical study enrollment completion
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}